AQR Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

AQR Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.51M	Buy	11,850 +1,536	+15%	+$192K	﹤0.01%	2537
2025 Q4	$1.26M	Buy	10,314 +2,926	+40%	+$335K	﹤0.01%	2429
2025 Q3	$740K	Buy	7,388 +576	+8%	+$51.9K	﹤0.01%	2602
2025 Q2	$565K	Buy	6,812 +1,834	+37%	+$146K	﹤0.01%	2549
2025 Q1	$404K	Buy	4,978 +2,167	+77%	+$194K	﹤0.01%	2548
2024 Q4	$253K	Buy	+2,811	New	+$272K	﹤0.01%	2577

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

AQR Capital Management's XBI Position: Q1 2026 in Review

AQR Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 15% in Q1 2026, buying an estimated $192K and bringing the position to 11,850 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2537.

AQR Capital Management first reported a position in XBI in Q4 2024 and has held it in 6 quarters since. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

AQR Capital Management held 11,850 shares of State Street SPDR S&P Biotech ETF worth $1.51M as of Q1 2026.
AQR Capital Management bought 1,536 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $192K.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2537 holding.
AQR Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 6 quarters since.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.